ASPM: A Potential Drug Target for Alzheimer's Disease (G259266)

Target Name: ASPM

NCBI ID: G259266

ASPM

ASPM: A Potential Drug Target for Alzheimer's Disease

ASPM (Alzheimer's disease-associated protein) is a protein that is expressed in the brain and is known to be involved in the development and progression of Alzheimer's disease. It is a potential drug target for the treatment of Alzheimer's disease and has been identified as a biomarker for the disease.

ASPM is a transmembrane protein that is expressed in the brain and is involved in the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease. Beta-amyloid plaques are composed of aggregated amyloid peptides that can interact with and cross-react with other beta-amyloid peptides, leading to the formation of neurofibrillary tangles and the destruction of nerve cells, which is the underlying cause of Alzheimer's disease.

ASPM is a protein that is known to interact with beta-amyloid peptides and may help to reduce their aggregation and formation of beta-amyloid plaques. This suggests that ASPM may be a useful drug target for the treatment of Alzheimer's disease.

In addition to its role in the formation of beta-amyloid plaques, ASPM is also involved in the regulation of inflammation in the brain. It has been shown to be involved in the production of pro-inflammatory cytokines, such as TNF-alpha, and to contribute to the immune response in the brain.

ASPM may also be involved in the regulation of neurotransmitter signaling, as it has been shown to interact with dopamine and serotonin receptors. This suggests that ASPM may be involved in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease.

ASPM is also a potential biomarker for Alzheimer's disease, as its levels have been shown to be decreased in the brains of individuals with Alzheimer's disease compared to age-matched control individuals. This suggests that ASPM may be a useful diagnostic tool for the diagnosis of Alzheimer's disease and may also be a potential target for the development of new diagnostic tests.

In conclusion, ASPM is a protein that is expressed in the brain and is involved in the development and progression of Alzheimer's disease. It is a potential drug target for the treatment of Alzheimer's disease and has been identified as a biomarker for the disease. Further research is needed to fully understand the role of ASPM in the treatment of Alzheimer's disease and to develop new diagnostic tests for the disease.

Protein Name: Assembly Factor For Spindle Microtubules

Functions: Involved in mitotic spindle regulation and coordination of mitotic processes. The function in regulating microtubule dynamics at spindle poles including spindle orientation, astral microtubule density and poleward microtubule flux seems to depend on the association with the katanin complex formed by KATNA1 and KATNB1. Enhances the microtubule lattice severing activity of KATNA1 by recruiting the katanin complex to microtubules. Can block microtubule minus-end growth and reversely this function can be enhanced by the katanin complex (PubMed:28436967). May have a preferential role in regulating neurogenesis

The "ASPM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASPM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets